HC Wainwright Issues Negative Forecast for RenovoRx Earnings

RenovoRx, Inc. (NASDAQ:RNXT) – Equities research analysts at HC Wainwright lowered their Q1 2026 earnings estimates for RenovoRx in a report issued on Wednesday, April 8th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.09) for the quarter, down from their previous estimate of ($0.08). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for RenovoRx’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.35) EPS.

Several other analysts have also weighed in on the stock. Ascendiant Capital Markets raised their price objective on shares of RenovoRx from $13.00 to $13.50 and gave the stock a “buy” rating in a report on Thursday. Wall Street Zen lowered shares of RenovoRx from a “hold” rating to a “strong sell” rating in a report on Saturday, April 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of RenovoRx in a report on Monday, December 29th. Finally, JonesTrading raised shares of RenovoRx to a “strong-buy” rating in a report on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.25.

RenovoRx Trading Up 0.7%

NASDAQ RNXT opened at $0.99 on Friday. The firm has a market cap of $44.39 million, a price-to-earnings ratio of -3.08 and a beta of 1.22. The company has a 50 day moving average of $0.95 and a 200-day moving average of $0.99. RenovoRx has a 1-year low of $0.70 and a 1-year high of $1.45.

RenovoRx (NASDAQ:RNXT) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.42 million. RenovoRx had a negative net margin of 994.48% and a negative return on equity of 119.77%. During the same quarter last year, the business posted ($0.40) earnings per share.

Institutional Trading of RenovoRx

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd boosted its stake in RenovoRx by 58.6% in the fourth quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after acquiring an additional 18,525 shares during the last quarter. Bleichroeder LP boosted its stake in RenovoRx by 11.4% in the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after acquiring an additional 61,379 shares during the last quarter. Wealthspire Advisors LLC bought a new position in RenovoRx in the fourth quarter valued at approximately $212,000. AIGH Capital Management LLC boosted its stake in RenovoRx by 8.4% in the fourth quarter. AIGH Capital Management LLC now owns 2,833,894 shares of the company’s stock valued at $2,380,000 after acquiring an additional 218,701 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in RenovoRx in the third quarter valued at approximately $154,000. Institutional investors and hedge funds own 3.10% of the company’s stock.

Trending Headlines about RenovoRx

Here are the key news stories impacting RenovoRx this week:

• Positive Sentiment: Ascendiant Capital Markets raised its price target from $13.00 to $13.50 and kept a “Buy” rating — a sizable upside compared with the current share price, which can attract speculative buying and headline interest. Article Title Ticker Report
• Positive Sentiment: A separate outlet reported a raised price target to $8.16 (up ~18.5%), which reinforces upbeat coverage from some brokers and can support momentum-based buying. MSN Article
• Positive Sentiment: HC Wainwright raised several multi-year estimates (FY2028–FY2030 and FY2029 marginally higher), signaling their longer-term view that RenovoRx could become profitable in later years — a positive cue for growth-oriented investors. MarketBeat RNXT
• Neutral Sentiment: Despite changes to estimates, HC Wainwright maintained a “Buy” rating and a $3.00 price target — this keeps a respected broker’s endorsement in place, but the target sits well above the current price and may be viewed as aspirational by some investors. MarketBeat RNXT
• Negative Sentiment: HC Wainwright trimmed near-term 2026 quarterly EPS forecasts (Q1–Q4 2026) and lowered FY2026 and FY2027 estimates, reflecting weaker short-term profitability expectations — this drove downward revisions to near-term guidance and is a headwind for the stock. MarketBeat RNXT

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.